Intestinal Transplantation With Alemtuzumab (Campath-1H) Induction for Adult Patients

S. Nishida, D. M. Levi, J. I. Moon, J. R. Madariaga, T. Kato, G. Selvaggi, P. Tryphonopoulos, W. DeFaria, S. Santiago, J. Gaynor, D. Weppler, E. Martinez, P. Ruiz, A. G. Tzakis

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Background: Alemtuzumab (Campath-1H [C1H]) is a humanized monoclonal antibody directed against the CD 52 antigen that is present on the surface of T cells, B cells, natural killer cells and monocytes. We studied its application in intestinal transplantation. Methods: This is a retrospective review of adult patients who underwent intestinal transplantation between December 1994 and May 2005. Group 1: non-C1H group (n = 39); group 2: C1H group (n = 37). C1H was administered as an induction immunosuppression in four doses (0.3 mg/kg), or in two doses (30 mg/kg). Tacrolimus levels were maintained at low level (5-10 ng/dL). No maintenance steroids were given. Results: One-year survival of group 1 and group 2 patients were 57% and 70%, respectively. This difference is not statistically significant. Of 37 patients in group 2, 21 are alive. The incidence of rejection was lower in group 2 (P < .005). Average current tacrolimus level is 6.97 ± 3.98 ng/dL. Seventeen patients (81%) are steroid free, and 15 (71%) are maintained solely on tacrolimus. There was no graft versus host disease in group 2. Conclusions: Our preliminary data suggest that C1H can provide effective immunosuppression for intestinal transplantation. Incidence of rejection was less with this regimen using low maintenance tacrolimus and minimal steroids.

Original languageEnglish (US)
Pages (from-to)1747-1749
Number of pages3
JournalTransplantation proceedings
Issue number6
StatePublished - Jul 2006

ASJC Scopus subject areas

  • Surgery
  • Transplantation


Dive into the research topics of 'Intestinal Transplantation With Alemtuzumab (Campath-1H) Induction for Adult Patients'. Together they form a unique fingerprint.

Cite this